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Relevant biochemicals of the brain can be quantified in vivo, non-invasively, using proton Magnetic Resonance
Spectroscopy (¹H MRS). This includes metabolites associated with neural general functioning, energetics, membrane
phospholipid metabolism and neurotransmission. Moreover, there is substantial evidence of implication of the frontal
and prefrontal areas in the pathogenesis of psychotic disorders such as schizophrenia. In particular, the anterior cingu-
late cortex (ACC) plays an important role in cognitive control of emotional and non-emotional processes. Thus the study
of its extent of biochemistry dysfunction in the early stages of psychosis is of particular interest in gaining a greater
understanding of its aetiology. In this review, we selected ¹H MRS studies focused on the ACC of first-episode psychosis
(FEP). Four studies reported increased glutamatergic levels in FEP, while other four showed preserved concentrations.
Moreover, findings on FEP do not fully mirror those in chronic patients. Due to conflicting findings, larger longitudinal
¹H MRS studies are expected to further explore glutamatergic neurotransmission in ACC of FEP in order to have a better
understanding of the glutamatergic mechanisms underlying psychosis, possibly using ultra high field MR scanners.
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The study of first-episode psychosis (FEP) patients is
of particular interest because it allows the investigation
of neurobiological processes, ruling out the effects of
long-term medications and chronicity (Squarcina
et al. 2015). Psychotic disorders are highly debilitating,
with symptoms ranging from delusions and hallucina-
tions to cognitive deficits (Altamura et al. 2015). In this
context, Proton Magnetic Resonance Spectroscopy
(¹H MRS) is the only non-invasive imaging technique
that can quantify the concentration of relevant bio-
chemicals in vivo in localised brain areas such as the
anterior cingulate cortex (ACC) (Benes & Berretta,
2001; Stanley, 2002; Brambilla et al. 2005). The ¹H
metabolites that are commonly reported include
N-acetylaspartate (NAA), a marker of functioning neu-
rons (Stanley et al. 2007), phosphocreatine plus creatine
(PCr + Cr), involved with energetic processes,
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glycerophosphocholine plus phosphocholine (GPC +
PC), catabolic and anabolic metabolites of membrane
phospholipids, and neurotransmitters, glutamine, glu-
tamate and gamma amino-butyric acid (GABA). ¹H
MRS has been largely employed in psychosis with
meta-analyses showing, in general, decreased NAA
levels in schizophrenia in prefrontal and temporal
areas (Kraguljac et al. 2012), while glutamate has
been found to be altered in schizophrenia and in indi-
viduals with a high risk of developing the disease,
especially in thalamus and prefrontal regions
(Marsman et al. 2013; Merritt et al. 2013). The investiga-
tion of brain metabolites can therefore be of help in
shedding light on the aetiology and biological mechan-
isms of psychosis.
Neuroanatomical models of schizophrenia are in
agreement with the hypothesis of a frontal lobe bio-
chemical alteration (Zabala et al. 2007). Thus, the
study of prefrontal integrity and function in the early
stages of the disease is of particular interest. The cingu-
late cortex, which is part of the cortico-striato-thalamo-
cortical networks, is involved in various cognitive
control and emotional processes. In particular, the evi-
dence is compelling in implicating the ACC in the
pathogenesis of schizophrenia (Baiano et al. 2007), par-
ticularly concerning negative symptoms (Hardy et al.
2011; Bersani et al. 2014). The neurobiology underlying
psychosis is still unclear: MRS techniques could allow
the identification of changes such as neuroplasticity or
neuropil loss (Théberge et al. 2002). In this review, we
consider studies, which focus on brain metabolites in
the ACC of FEP patients measured with 1H MRS. A
bibliographic search on PUBMED on MRS studies
exploring ACC in FEP was performed. The search
terms used to identify the articles of interest were
‘MRS’, ‘spectroscopy’, ‘anterior cingulate’, ‘first epi-
sode psychosis’. Ten papers, which have been sum-
marised in Table 1, met these inclusion criteria.
Four out of the ten studies reported increased gluta-
matergic function (considered as glutamate, glutamine
or glutamate plus glutamine) in FEP, whereas four
studies showed preserved levels. Just one study
reported changes in creatine (Tibbo et al. 2013). Going
into details, Thèberge et al. (2002) found higher levels
of glutamine, and no other metabolites, in the left
anterior ACC of FEP, in accordance with the hypothe-
sised abnormal glutamatergic activity in schizophrenia
(Marsman et al. 2013). These results in FEP were con-
firmed in a 2007 study (Théberge et al. 2007): interest-
ingly, glutamine levels did not decrease after 30
months of follow-up, suggesting that the lower levels
found in chronic illness by the same group (Théberge
et al. 2003), may need more time to appear. An associ-
ation between glutamine and FEP has been highlighted
also by the fact that its levels were found to be
associated with patient performance in neuropsycho-
logical tests, such as the Wisconsin Card Sorting Test,
the Paced Auditory Serial Addition Task and the
Trail Making Test B (Dempster et al. 2015). An involve-
ment of the glutamatergic function in the early stage of
disease in frontal regions has also been confirmed by
several studies, which found altered levels of gluta-
mate. In particular, increased glutamate levels were
reported in prefrontal areas of FEP (Smesny et al.
2015), including the anterior ACC. Smesny et al.
(2015) hypothesised that glutamate is linked with cellu-
lar energy and membrane lipids metabolism, suggest-
ing a relationship with membrane atypical behavior.
This indicates that medication targeting neuroprotec-
tion could be of great importance especially at the
early stages of disease. Levels of glutamate were
found to be higher in non-remitted patients in respect
to remitted patients, when compared after anti-
psychotic treatment, and to be associated with lower
functioning and worse negative symptoms (Egerton
et al. 2012). This indicates that the clinical status of
patients could be related with glutamatergic dysfunc-
tion, which might then be targeted in patients, espe-
cially those not responding to antipsychotics. Results
on glutamatergic function in FEP are not always in
agreement, as some studies did not find differences
between groups (Galinska et al. 2009; Tibbo et al.
2013). This could be related to the exact positioning
of the voxel in the ACC. For example, Tibbo et al.
(2013) positioned the voxel in the medial prefrontal
region, including only part of anterior ACC. All studies
considering NAA levels did not find any difference in
the ACC of FEP compared with healthy subjects, even
when finding differences in chronic schizophrenia
patients (Natsubori et al. 2014), possibly indicating
that neuronal integrity, linked with NAA, is related
to the progression of disease.
Finally, Tibbo et al. (2013) reported a significant
reduction in PCr + Cr of FEP compared with controls.
Both PCr and Cr are involved in the processes related
with cellular energy: thus, the authors have hypothe-
sised that schizophrenia is associated with dysregula-
tion in maintaining adequate energy pools. Other
studies which considered PCr + Cr in their analyses
(Théberge et al. 2002, 2007; Egerton et al. 2012; Tibbo
et al. 2013; Natsubori et al. 2014; Dempster et al. 2015)
reported pressured PCr + Cr levels in FEP. It has to
be noted though that Tibbo et al. (2013) utilised an
ad-hoc MRS sequence with a long TE (240 ms) and
the specific aim of quantifying mainly Cr, which
could be accounted for the difference in results in
respect to the other studies.
In summary, although there are some findings on
increased glutamatergic levels in the ACC of FEP,
they are still partially conflicting since some ¹H MRS
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Table 1. Selection of studies on first-episode psychosis investigating anterior cingulate cortex metabolism with 1-H magnetic resonance spectroscopy
Study
Sample size
(mean age ± S.D.) Study design
Field
strength
SV or CSI and location
(voxel size)
Short or
intermediate
Echo time
(TE time)
Quantification
and reported ¹
H metabolites
ACC results only (if possible,
include the effect size in
brackets for each
significant finding)
Théberge
et al.
(2002)
21 FEP (26 ± 7 y.o.),
21 HC (26 ± 7
y.o.)
Cross-sectional and investigated
group differences
4 T SV
Left anterior ACC (1.5 cc) and
left medial thalamus (1.5 cc)
Short TE (20 ms) Absolute relative
to water (only
NAA
Glu
Gln
GPC + PC
PCr + Cr
Taurine
scyllo-Ins
myo-Ins)
Increased Gln in the left ACC
Théberge
et al.
(2004)
19 FEP (25 ± 8 y.o.) Cross-sectional 4 T SV
Left anterior ACC and left
thalamus (1.5 cc)
Short TE (20 ms) Absolute relative
to water
NAA
GPC + PC
Positive correlation between
GPC + PC and duration of
untreated psychosis
Blasi et al.
(2004)
17 FEP (26.8 ± 7.6
y.o.), 17 HC (25.5
± 6.8 y.o.)
Cross-sectional and investigated
group differences
1.5 T CSI (7.5 × 7.5 × 15 mm – 0.84
ml)
Four slices
Left and right
ACC (0.84 cc each) plus other
ROIs
Long TE (272
ms)
Metabolite ratios
NAA/PCr + Cr
NAA/GPC + PC
GPC + PC/PCr
+ Cr
No significant group
differences in the right and
left ACC
Théberge
et al.
(2007)
16 FEP (25 ± 8 y.o.),
16 HC (29 ± 12
y.o.)
Longitudinal study design
where patients were assessed
three times (at baseline, after
10 months of treatment, after
30 months of treatment) and
HC assessed twice 35 months
apart
4 T SV
left anterior ACC and left
medial thalamus (10 × 10 ×
15 mm3 each)
Short TE (20 ms) Absolute relative
to water
NAA
Glu
Gln
GPC + PC
PCr + Cr
myo-Ins
Taurine
scyllo-Ins
At baseline, increased Gln in
the left ACC
No significant effect for the
three-level repeated-
measures analysis
No correlations with clinical
scores
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Uhl et al.
(2011)
24 FEP (26 ± 6.3
y.o.), 30 UHR
(25.6 ± 4.5 y.o.),
31 HC (25.5 ± 5.2
y.o.)
Cross-sectional and investigated
group differences
1.5 T SV
Left hippocampus, mid-sagittal
ACC, MPFC (8 ml each)
Intermediate TE
(140 ms)
Metabolite ratios
GPC + PC/Cr
NAA/Cr
No significant group
differences
Egerton
et al.
(2012)
32 FEP (30 ± 6 y.o.) Cross-sectional and investigated
group differences
3 T SV
Medial anterior ACC (20 × 20 ×
20 mm3), centre of left
thalamus (15 × 20 × 20 mm3)
Short TE (30 ms) Metabolite ratios
Glu/Cr
Glu + Gln/Cr
NAA/Cr
GPC + PC/Cr
myo-Ins/Cr
Increased levels of Glu/Cr in
the ACC of non-remitted
patients
Higher levels of Glu/Cr in
the anterior cingulate cortex
were associated with a
greater severity of negative
symptoms and a lower level
of global functioning
Tibbo et al.
(2013)
33 FEP (21.6 ± 3.4 y.
o.), 41 HC (21.9 ±
3.1 y.o.)
Cross-sectional and investigated
group differences
3 T SV
Medial prefrontal region
including part of anterior
ACC (20 × 30 × 30 mm3)
Short TE (20 ms) Absolute relative
to water
NAA
PCr + Cr
GPC + PC
Glu
A negative association was
found between age of
patients and Cr
16% reduction of Cr levels
in patients
No association between Cr
and clinical variables
Natsubori
et al.
(2014)
24 UHR (21.7 ± 3.8
y.o.) with 26
matched HC
(22.3 ± 3.2 y.o.),
19 FEP (25.4 ± 6.3
y.o.) with
19 matched
controls (26.3 ±
1.5 y.o.), 25 scz
(32.7 ± 8.6 y.o.)
with 28 matched
HC (32.8 ± 4.3
y.o.)
Cross-sectional and investigated
group differences
3 T SV
MPFC – primarily ACC and
left and right paracingulate
gyri (20 × 20 × 20 mm3)
Short TE (15 ms) Absolute relative
to water
NAA
Glu + Gln
PCr + Cr
GPC + PC
myo-Ins
Reduced levels of NAA and
Glu + Gln in the MPFC in
scz but not FEP FES or UHR
Continued
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nterior
cingulate
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Table 1. Continued
Study
Sample size
(mean age ± S.D.) Study design
Field
strength
SV or CSI and location
(voxel size)
Short or
intermediate
Echo time
(TE time)
Quantification
and reported ¹
H metabolites
ACC results only (if possible,
include the effect size in
brackets for each
significant finding)
Dempster
et al.
(2015)
16 FEP (17 ± 7.2
y.o.)
Longitudinal study with
patients assessed at baseline
and after 10 months
4 T SV (1.5 cm3)
left ACC, left thalamus
Short TE (20 ms) Absolute relative
to water
Glu,
Gln
Baseline Gln was positively
associated with
performance on the PASAT
in the left ACC,
Glu at the 10-month
scanning point was
positively associated with
TrailsB duration and with
WCST perseverative errors
Glutamine at 10- month
scanning was positively
associated with WCST
perseverative errors and
negatively associated with
WCST
Smesny
et al.
(2015)
31 FEP (25.97 ± 4.95
y.o.), 31 HC
(25.42 ± 5.18 y.o.)
Cross-sectional and investigated
group differences
3 T CSI
region of interest selected in
the frontal part of the CSI
slab: 8 voxels including (left
and right) frontal prefrontal
cortex and ACC (15 × 9 × 1.5
cm3) each voxel
Short TE (30 ms) Absolute
concentrations
Glu
Increased levels of Glu in FEP
Glu positively correlated
with frontal/prefrontal PME
and right frontal/prefrontal
PDE in FEP and not in HC
Glu negatively correlated
with PCr or ATP values in
the frontal/prefrontal cortex
bilaterally and in the right
ACC in HC and not in
patients
MRS, magnetic resonance spectroscopy; FEP, first episode psychosis; SV, single voxel; CSI, chemical shift imaging; HC, healthy controls; SCZ, schizophrenia; WM, white matter; GM, gray
matter; CSF, cerebro-spinal fluid; ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; MPFC, medial prefrontal cortex; NAA, N-acetylaspartate; NAAG, N-acetylaspar-
tylglutamate; Gln, glutamine; Glu, glutamate; Glc, glucose; PCr + Cr, phosphocreatine + creatine; GPC + PC, glycerophosphocholine + phosphocholine; mI, myo-Inositol; myo-Ins, myo-inosi-
tol; scyllo-Ins, scyllo-Inositol; TE, echo time; y.o., years old.
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studies found preserved concentrations. Moreover,
results in FEP do not fully overlap with those in
chronic schizophrenia. This could be due to the fact
that metabolite levels are particularly sensitive to the
characteristics of the sample, and to the phase of dis-
ease. Therefore, although glutamatergic neurotrans-
mission may play a role in the pathophysiology of
psychosis onset, the fact that findings are somewhat
heterogeneous suggests that a more in-depth investiga-
tion is needed to shed light on the glutamatergic pro-
cesses related to psychosis, by implementing larger
longitudinal studies of FEP using ultra high field MR
scanners.
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